期刊文献+

高脂血症与前列腺癌的相关性研究 被引量:5

Correction between Hyperlipoidemia and Prostate Cancer: A Clinical Study
原文传递
导出
摘要 目的探讨高脂血症与前列腺癌发生及临床进展的相关性。方法对福建医科大学附属漳州市医院收治的112例疑似前列腺癌经前列腺穿刺活检病理证实并行前列腺癌根治术的患者进行回顾性分析。结果 112例患者中合并高脂血症64例(57.14%)。与单纯前列腺癌相比,前列腺癌合并高脂血症的患者发病年龄明显较小(65.0±5.0岁vs.67.8±3.7岁,P=0.001),前列腺体积更大(75.0±11.7 mL vs.54.5±8.5 mL,P<0.001),血清总前列腺特异性抗原(TPSA)水平明显升高(61.4±23.3 ng/mL vs.33.4±14.9 ng/mL,P<0.001),TNM临床分期明显更晚(P<0.001),Gleason评分明显升高(6.9±1.8 vs.5.0±1.9,P<0.001),生存时间更短(49.8±12.7月vs.57.3±6.2月,P<0.001),五年生存率(5-YSR)明显降低(51.6%vs.77.1%,P=0.006)。胆固醇的升高、甘油三脂的升高和高密度脂蛋白的降低与发病年龄年轻化、前列腺体积增大、TPSA水平升高、TNM临床分期及Gleason评分升高、生存时间缩短及5-YSR下降密切相关(P<0.05)。多因素分析结果显示高脂血症(OR=3.204,P=0.022)和Gleason评分(OR=8.611,P<0.001)是患者预后的独立危险因素。结论前列腺癌合并高脂血症临床多见,高脂血症有可能是前列腺癌发生与临床进展的危险因素之一。 ObjectiveTo assess whether hyperlipoidemia affects the occurrence and progression of prostate cancer (PCA). MethodsA hospital based retrospective study was carried out in Zhangzhou Affiliated Hospital of Fujian Medical University using data from a total of 112 cases of PCA, which underwent radical prostatectomy due to suspected PCA and confirmed by prostate biopsy pathology. ResultsOf the 112 PCA patients, 64 (57.14%) were PCA with hyperlipoidemia (PCA-H). Compared with PCA patients, the patients of PCA-H patients had younger onset age (65.0±5.0 vs. 67.8±3.7, P=0.001), increased prostate volume (75.0±11.7 mL vs. 54.5±8.5 mL, P〈0.001), increased level of TPSA (61.4±23.3 ng/mL vs. 33.4±14.9 ng/mL, P〈0.001), and Gleason grade (6.9±1.8 vs. 5.0±1.9, P〈0.001), later clinical stage (P〈0.001), shorter survival time (49.8±12.7 months vs. 57.3±6.2 months, P〈0.001) and decreased 5 years of survival rate (51.6% vs. 77.1%, P=0.006). The level of cholesterol, triglyceride and high density lipoprotein was significantly associated with the rejuvenation of onset age, the enlargement of prostate volume, increasing of serum TPSA, the progression of TNM clinical stage, increasing of Gleason grade, shorten of survival time and dropping of 5 years of survival rate (P〈0.05). In multiple-factor regression analysis, only hyperlipoidemia (OR=3.204, P=0.022) and Gleason grade (OR=8.611, P〈0.001) were the independent risk factors of prognosis. ConclusionThe situation of PCA with hyperlipoidemia is frequently noted in clinics, and hyperlipoidemia may be one of the risk factors in the processes of PCA growth and progression.
出处 《中国循证医学杂志》 CSCD 2014年第4期414-417,共4页 Chinese Journal of Evidence-based Medicine
关键词 前列腺癌 高脂血症 危险因素 Prostate cancer Hyperlipoidemia Risk factor
  • 相关文献

参考文献15

  • 1Ma RW, Chapman K. A systematic review of the effect of diet in prostate cancer prevention and treatment.J Hum Nutr Diet, 2009, 22(3): 187-199.
  • 2Bratt O. Hereditary prostate cancer: clinical aspects.J Urol, 2002, 168(3): 906-913.
  • 3Meyer F, Bairati I, Shadmani R, et al. Dietary fat and prostate cancer survival. Cancer Causes Control, 1999, 10(4): 245-251.
  • 4Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci, 2006, 11(5): 1388-1413.
  • 5Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Can- cer I Clin, 2011, 61(2): 134.
  • 6赵平,陈万青.中国肿瘤登记年报.北京:中国协和医科大学,2004.
  • 7李鸣,张思维,马建辉,陈万青,那彦群.中国部分市县前列腺癌发病趋势比较研究[J].中华泌尿外科杂志,2009,30(6):368-370. 被引量:172
  • 8Hammarsten J, Hogstedt B. Clinical, haemodynamic, anthropomet- ric, metabolic and insulin profile of men with high stage and high grade clinical prostate cancer. Blood Pressure, 2004, 13(1): 47-455.
  • 9Hammarsten J, H6gstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur I Cancer, 2005, 41(18):2887-2895.
  • 10Mittal A, Sathian B, Chandrasekharan N, et al. Role of hypercho- lesterolemia in prostate cancer-case control study from Manipal Teaching Hospital Pokhara, Nepal. Asian PacJ Cancer Prey, 2011, 12(8): 1905-1907.

二级参考文献14

  • 1张思维,陈万青,孔灵芝,李连弟,鲁凤珠,李光琳,孟佳,赵平.中国部分市县1998~2002年恶性肿瘤的发病与死亡[J].中国肿瘤,2006,15(7):430-448. 被引量:171
  • 2李连弟,饶克勤.中国试点市县恶性肿瘤的发病与死亡第1卷(1988-1992).北京:中国医药科技出版社,2002:263-289.
  • 3李连弟,饶克勤.中国试点市县恶性肿瘤的发病与死亡第2卷(1993-1997).北京:中国医药科技出版社,2003:269-295.
  • 4李连弟,饶克勤,孔灵芝,等.中国试点市县恶性肿瘤的发病与死亡第3卷(1999-2002).北京:人民卫生出版社,2007:314-316.
  • 5Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Vol. VIII. IARC Scientific Publication No. 155. Lyon: IARC, 2002: 745-747.
  • 6Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Vol. IX. IARC Scientific Publication No. 160. Lyon: IARC, 2008.
  • 7Jensen OM, Parkin DM, MacLennan R, et al. Cancer registration: principles and methods. IARC Scientific Publication No. 95. Lyon.. IARC, 1991.. 101-107.
  • 8Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19. Lyon.. IARC, 1994: 35-49.
  • 9Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC Technical Report No. 42. Lyon: IARC, 2005: 11-38.
  • 10Felay J. The IARCcrgTools program, http://www, iacr. com. fr/iarccrgtools, htm. IACR. Lyon. 2006.

共引文献171

同被引文献52

  • 1张健强,赵征宇,张薇,黎明,任鸿伟,蔡定均.基于CiteSpace的子午流注针法知识图谱分析[J].世界科学技术-中医药现代化,2020,22(8):2727-2735. 被引量:20
  • 2陈悦,陈超美,刘则渊,胡志刚,王贤文.CiteSpace知识图谱的方法论功能[J].科学学研究,2015,33(2):242-253. 被引量:9411
  • 3Jemal A, Bray F, Center MM, et al.Global cancer statistics[J]. CA Cancer JClin, 2011,61(2):69-90.
  • 4Ma RW, Chapman K. A systematicreview of the effect of diet in prostatecancer prevention and treatment[J]. JHum Nutr Diet, 2009, 22(3):187-199.
  • 5Breau RH, Karnes KJ, Jacobson DJ, etal. The association between statin useand the diagnosis of prostate cancerin a population based cohort[J].y Urol,2010, 184(2):494-499.
  • 6Bielecka-Dbrowa A, Hannam S,Rysz J, et al. Malignancy-associateddyslipidemia[J]. Open Cardiovasc MedJ, 2011, 5:35-40.
  • 7Freeman MR, Solomon KR. Cholesteroland prostate cancer[J].y Cell Biochem,2004,91(1):54-69.
  • 8Di Vizio D, Solomon KR, FreemanMR. Cholesterol and cholesterol-rich membranes in prostate cancer:an update [J]. Tumori, 2008,94(5):633-639.
  • 9Zhou Q, Liao JK. Statins andcardiovascular diseases:from cholesterol lowering topleiotropy[J]. Curr Pharm Des, 2009,15(5):467-478.
  • 10Shannon J, Tewoderos S, GarzottoM, et al.. Statins and prostate cancerrisk: a case-control study[J]. Am JEpidemiol, 2005, 162(4):318-325.

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部